RecruitingNCT05311137

Study of the Closed-loop Treatment Concept of Atrial Fibrillation in the Atrial Fibrillation Population

Application of the Closed-loop Treatment Concept of Atrial Fibrillation in the Atrial Fibrillation Population in the Northern Shanghai Community


Sponsor

Shanghai 10th People's Hospital

Enrollment

5,000 participants

Start Date

May 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to evaluate the concept of closed-loop treatment of atrial fibrillation for the optimization of the treatment strategy.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study tracks the treatment and outcomes of patients with atrial fibrillation (AFib) — an irregular heart rhythm — to evaluate a comprehensive, coordinated approach to managing the condition. The goal is to understand how a "closed-loop" care model (where treatment is continuously adjusted based on patient response) compares to standard care. **You may be eligible if...** - You have been diagnosed with atrial fibrillation - You are able to make your own decisions and sign an informed consent form **You may NOT be eligible if...** - There are no formal exclusion criteria — all patients with atrial fibrillation are welcome to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURERadiofrequency ablation

Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.


Locations(1)

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05311137


Related Trials